Indeed, Casp2 inhibition may lead to reduced lipoapoptosis and steatohepatitis, and block the production of fibrogenic Hedgehog ligands, which aggravate NASH progression [11, 50]. The gene discussed is CASP2; the disease is metabolic dysfunction-associated steatohepatitis.